In 2002, Iwai et al. provided the initial evidence of PD-1 signaling pathway involvement in mediating tumor immunity [15], and it is now widely recognized that tumor cells can also exploit immune checkpoints to suppress tumor immunity and evade immune surveillance [16, 17]. This evidence concerns the gene PDCD1 and neoplasm.